Combination therapy in invasive mucormycosis

作者
Meera D. Shah,Emily A Gibbons,Gloria Christina Gutierrez
标识
DOI:10.25259/ajpps_2025_014
摘要

Objectives: Mucormycosis is a rare and aggressive mold infection with an all-cause mortality of 54%. Treatment has historically been high-dose liposomal amphotericin B (LAmB) monotherapy. Recent data on combination therapies are conflicting, and their benefit remains unclear. This case series explores different combination therapies for mucormycosis and their effects on mortality. Materials and Methods: We report 17 cases of probable or proven mucormycosis managed with combination therapy for at least 48 h at University Hospital between March 2020 and November 2022. Results: The median age of patients was 60 years old (range 21–74), 11 patients were male (64.7%), and the median body mass index was 27.8 kg/m 2 . Of the 17 patients, all patients (100%) were Hispanic, nine patients (53%) had diabetes, and two patients (12%) were lung transplant recipients. The most common infection site was rhino-orbital (6/17; 35%), and surgery was performed on 11 patients (64.7%) after a median of 2 days after hospital admission. All 17 patients received LAmB with an average initial dose of 5.13 mg/kg/day (range 2.9– 6.4 mg/kg/day). All patients received combination therapy with either posaconazole (6/17; 35.2%), micafungin (4/17; 23.5%), or triple therapy (7/17; 41.2%). The duration of combination therapy was a median 6 days (range 2–21 days). Five of the 17 patients (29%) died of mucormycosis-related complications. Mortality observed in patients receiving combination therapy is as follows: micafungin combination (4/4; 100%), posaconazole combination (5/6; 83%), and triple therapy (0/7; 0%). Conclusion: Mucormycosis is an aggressive fungal infection with high morbidity and mortality requiring immediate recognition and medical intervention with an appropriate antifungal dosing regimen. Combination therapy with micafungin may be associated with higher mortality than posaconazole or triple therapy. In this cohort, combination therapy may have lower mortality than previously documented, but further investigation is needed to determine the optimal treatment for invasive mucormycosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
云弦发布了新的文献求助10
刚刚
1秒前
Kobe发布了新的文献求助10
1秒前
Lucas的应助被平常破茧采纳,获得10
1秒前
1秒前
awen完成签到,获得积分10
2秒前
2秒前
2秒前
zxz发布了新的文献求助10
2秒前
Slaimigo发布了新的文献求助10
3秒前
3秒前
Lucas的应助被小凯采纳,获得10
3秒前
高山的应助被调皮汽车采纳,获得50
3秒前
3秒前
3秒前
高天完成签到,获得积分10
3秒前
3秒前
3秒前
4秒前
领导范儿的应助被刘谋采纳,获得10
4秒前
4秒前
Juvenilesy的应助被sinmon采纳,获得10
4秒前
4秒前
我是老大的应助被jdmeme采纳,获得10
4秒前
4秒前
852的应助被午凌二采纳,获得10
4秒前
5秒前
guoleileity完成签到,获得积分10
5秒前
挚友发布了新的文献求助10
5秒前
秋风的应助被科研通管家采纳,获得20
5秒前
我是老大的应助被科研通管家采纳,获得10
5秒前
Marcia完成签到,获得积分10
5秒前
上官若男的应助被科研通管家采纳,获得10
5秒前
朱婷完成签到,获得积分10
5秒前
大模型的应助被科研通管家采纳,获得10
5秒前
null的应助被科研通管家采纳,获得10
5秒前
nn114发布了新的文献求助10
5秒前
bkagyin的应助被科研通管家采纳,获得10
6秒前
蓝天的应助被科研通管家采纳,获得10
6秒前
Criminology34的应助被科研通管家采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161857
求助须知:如何正确求助?哪些是违规求助? 9556272
关于积分的说明 21733778
捐赠科研通 7751772
什么是DOI,文献DOI怎么找? 3427616
关于科研通互助平台的介绍 2552632
邀请新用户注册赠送积分活动 2472079